
Many serious or potentially fatal adverse reactions associated with new, targeted anti-cancer agents are not reported in the original published research on the drug, and they are not known to oncologists until years later when drug labels are updated, including boxed warnings, according to research published online in the Journal of Clinical Oncology, HealthDay News reported.



